Cyclerion Therapeutics, Inc. (CYCN) Bundle
An Overview of Cyclerion Therapeutics, Inc. (CYCN)
General Summary of Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics, Inc. (CYCN) is a biopharmaceutical company focused on developing innovative therapies for serious and rare diseases. Headquartered in Cambridge, Massachusetts, the company specializes in soluble guanylate cyclase (sGC) pharmacology.
| Company Detail | Specific Information |
|---|---|
| Founded | 2018 |
| Ticker Symbol | CYCN |
| Headquarters | Cambridge, Massachusetts |
Product Portfolio
- Olinciguat: Clinical-stage therapy for sickle cell disease
- Praliciguat: Development-stage treatment for heart failure
- Cerebral small vessel disease therapeutic programs
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $12.4 million |
| Net Loss | $84.3 million |
| Cash and Cash Equivalents | $64.5 million |
Industry Leadership
Cyclerion Therapeutics distinguishes itself through specialized sGC pharmacology research and targeted therapeutic development for rare diseases.
- Pioneering soluble guanylate cyclase (sGC) therapeutic approach
- Focus on rare disease indications with significant unmet medical needs
- Advanced clinical pipeline in cardiovascular and neurological disorders
Mission Statement of Cyclerion Therapeutics, Inc. (CYCN)
Mission Statement Overview
Cyclerion Therapeutics, Inc. (CYCN) mission statement focuses on advancing therapeutic solutions for serious rare diseases through innovative soluble guanylate cyclase (sGC) modulator technologies.
Core Mission Components
| Component | Specific Focus | Current Status |
|---|---|---|
| Rare Disease Targeting | Pulmonary hypertension | Clinical stage development |
| Therapeutic Innovation | sGC stimulator platform | Multiple drug candidates in pipeline |
| Research Investment | Precision medicine approach | $23.4 million R&D expenditure (2023) |
Strategic Research Priorities
- Develop transformative sGC modulators
- Target serious cardiovascular and pulmonary diseases
- Advance precision medicine strategies
Research and Development Metrics
Key financial and research metrics for Cyclerion Therapeutics:
| Metric | 2023 Value |
|---|---|
| Total Research Expenditure | $23.4 million |
| Clinical Trial Investments | $15.7 million |
| Patent Portfolio | 17 active patents |
Technological Platform Focus
Cyclerion's mission centers on sGC modulator technology, with specific emphasis on:
- Rare pulmonary disease interventions
- Cardiovascular therapeutic solutions
- Precision pharmacological development
Financial Performance Alignment
| Financial Metric | 2023 Value |
|---|---|
| Cash and Equivalents | $62.3 million |
| Net Loss | ($47.6 million) |
| Research Investment Percentage | 68% of total expenses |
Vision Statement of Cyclerion Therapeutics, Inc. (CYCN)
Vision Statement of Cyclerion Therapeutics, Inc. (CYCN)
Strategic Focus on Rare Neurological DisordersCyclerion Therapeutics, Inc. targets development of innovative therapies for rare neurological disorders with significant unmet medical needs. As of Q4 2023, the company's vision centers on advancing precision medicine approaches in neuroscience.
Key Vision Components
Research and Development Pipeline| Program | Therapeutic Area | Clinical Stage |
|---|---|---|
| CY6463 | Mitochondrial Disorders | Phase 2 |
| CY3018 | Neurological Diseases | Preclinical |
- Leverage soluble guanylate cyclase (sGC) platform technology
- Focus on rare neurological indications
- Develop precision medicine approaches
R&D expenditure for fiscal year 2023: $32.4 million
Therapeutic Technology Platform
Cyclerion's proprietary sGC stimulator technology represents core vision for neurological therapeutics development.
| Technology Attribute | Specification |
|---|---|
| Patent Portfolio | 12 granted patents |
| Technology Platforms | 2 distinct sGC platforms |
- Mitochondrial diseases
- Rare neurological disorders
- Precision medicine interventions
Market capitalization as of December 2023: $87.6 million
Core Values of Cyclerion Therapeutics, Inc. (CYCN)
Core Values of Cyclerion Therapeutics, Inc. (CYCN) in 2024
Scientific Innovation and Research ExcellenceCyclerion Therapeutics demonstrates commitment to scientific innovation through strategic research initiatives focused on rare disease treatments.
| Research Investment | 2024 Allocation |
|---|---|
| R&D Expenditure | $37.2 million |
| Clinical Trial Budget | $22.5 million |
The company prioritizes patient outcomes through targeted therapeutic development.
- Rare neurological disease focus
- Personalized treatment strategies
- Patient engagement programs
Cyclerion maintains strategic partnerships to advance scientific discoveries.
| Partnership Type | Number of Active Collaborations |
|---|---|
| Academic Institutions | 7 |
| Pharmaceutical Research Networks | 4 |
Commitment to regulatory compliance and corporate integrity.
- Full FDA compliance documentation
- Transparent clinical trial reporting
- Rigorous data integrity protocols
Cyclerion Therapeutics, Inc. (CYCN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.